Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 4/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.68 |
| ▸ | BLM | P54132 | 2/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | FTO | Q9C0B1 | 5/20 | 0.65 |
| ▸ | RGS12 | O14924 | 1/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31618898 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTHPGDMEN1KMT2A | |
| SCHEMBL11202635 | 0.92 | ALDH1A1 (0.85) | ALDH1A1MAPTHPGDMEN1KMT2A | |
| SCHEMBL10144274 | 0.91 | ALDH1A1 (0.84) | ALDH1A1MAPTHPGDMEN1KMT2A | |
| SCHEMBL8848281 | 0.82 | FTO (0.74) | ALDH1A1MAPTHPGDMEN1KMT2A | |
| SCHEMBL8848276 | 0.82 | FTO (0.74) | ALDH1A1MAPTHPGDMEN1KMT2A | |
| SCHEMBL8848272 | 0.82 | FTO (0.74) | ALDH1A1MAPTHPGDMEN1KMT2A | |
| SCHEMBL20100865 | 0.82 | FTO (0.74) | ALDH1A1MAPTHPGDMEN1KMT2A | |
| SCHEMBL4940498 | 0.81 | FTO (0.73) | ALDH1A1MAPTHPGDMEN1KMT2A | |
| SCHEMBL15920344 | 0.81 | FTO (0.73) | ALDH1A1MAPTHPGDMEN1KMT2A | |
| SCHEMBL20100868 | 0.81 | FTO (0.73) | ALDH1A1MAPTHPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12616733-B2 | XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260041767-A1 | METHODS OF IMPROVING CELLULAR THERAPY WITH ORGANELLE COMPLEXES | UNIV HOKKAIDO NAT UNIV CORP (JP) | 2026-02-12 | — | — | US | disclosed |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250290915-A1 | METHOD FOR PREDICTING RESPONSIVENESS TO THERAPY | Cancertain Limited (GB) | 2025-09-18 | — | — | US | disclosed |
| US-12359208-B2 | Thermal control of T-cell immunotherapy through molecular and physical actuation | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2025-07-15 | — | — | US | disclosed |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2025-06-24 | — | — | US | disclosed |
| EP-4565684-A1 | METHODS OF IMPROVING CELLULAR THERAPY WITH ORGANELLE COMPLEXES | National University Corporation Hokkaido University (JP) | 2025-06-11 | — | — | EP | disclosed |
| WO-2025106862-A1 | METHODS OF TREATING KIT POSITIVE CANCERS WITH A MENIN INHIBITOR | KURA ONCOLOGY, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| EP-4515230-A2 | METHOD FOR PREDICTING RESPONSIVENESS TO THERAPY | Cancertain Limited (GB) | 2025-03-05 | — | — | EP | disclosed |
| US-12220423-B2 | Compounds, derivatives, and analogs for cancer | HYGIA PHARMACEUTICALS, LLC (US) | 2025-02-11 | — | — | US | disclosed |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2022-11-08 | — | — | US | disclosed |
| WO-2022212005-A2 | ACOUSTIC REMOTE CONTROL OF MICROBIAL IMMUNOTHERAPY | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-10-06 | — | — | WO | disclosed |
| US-20220290162-A1 | ACOUSTIC REMOTE CONTROL OF MICROBIAL IMMUNOTHERAPY | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2022-09-15 | — | — | US | disclosed |
| US-20220280519-A1 | COMBINATIONS OF AGENTS TO TREAT HEMATOLOGICAL MALIGNANCIES | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2022-09-08 | — | — | US | disclosed |
| WO-2022125590-A1 | A SYNTHETIC CIRCUIT FOR CELLULAR MULTISTABILITY | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-06-16 | — | — | WO | disclosed |
| US-20220177911-A1 | SYNTHETIC CIRCUIT FOR CELLULAR MULTISTABILITY | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2022-06-09 | — | — | US | disclosed |
| US-20220064666-A1 | SYNTHETIC MAMMALIAN SIGNALING CIRCUITS FOR ROBUST CELL POPULATION CONTROL | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2022-03-03 | — | — | US | disclosed |
| US-20180179594-A1 | MULTIPLE SYSTEM ATROPHY AND THE TREATMENT THEREOF | PARKINSON'S INSTITUTE | 2018-06-28 | — | — | US | disclosed |
| US-20180179594-A1 | MULTIPLE SYSTEM ATROPHY AND THE TREATMENT THEREOF | PARKINSON'S INSTITUTE | 2018-06-28 | — | — | US | disclosed |
| US-20120022116-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | CORNING INCORPORATED | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | ALDH1A1 379/4885MAPT 4222/4885HPGD 958/4885 |
| US-20260041767-A1 | METHODS OF IMPROVING CELLULAR THERAPY WITH ORGANELLE COMPLEXES | TFAM, FIS1, TUFM | ALDH1A1 4231/4885MAPT 655/4885HPGD 3561/4885 |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | ALDH1A1 379/4885MAPT 4222/4885HPGD 958/4885 |
| US-20120022116-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | GPR35, GPR65, GPR68 | ALDH1A1 1572/4885MAPT 3699/4885HPGD 1017/4885 |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | ALDH1A1 379/4885MAPT 4222/4885HPGD 958/4885 |
| US-12616733-B2 | XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions | XBP1, MCL1, CD81 | ALDH1A1 4207/4885MAPT 2741/4885HPGD 4656/4885 |
| US-12220423-B2 | Compounds, derivatives, and analogs for cancer | KRAS, PIK3CA, PIK3CD | ALDH1A1 2145/4885MAPT 4805/4885HPGD 1768/4885 |
| US-20220280519-A1 | COMBINATIONS OF AGENTS TO TREAT HEMATOLOGICAL MALIGNANCIES | MCL1, MPL, BCL9 | ALDH1A1 1620/4885MAPT 4865/4885HPGD 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.